Several studies have shown that TILs are associated with favorable long-term prognosis and better response to therapy in HER2-positive breast cancer.7 In the early setting, a clinical study with 232 HER2+ BC patients (FinHer trial) were randomized to receive adjuvant chemotherapy with or without Trastuzumab. Here, ERBB2 is linked to breast cancer.